Tobacco company Philip Morris International (NYSE:PM) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.8% year on year to $10.36 billion. Its non-GAAP profit of $1.70 per share was in line with analysts’ consensus estimates.
Is now the time to buy PM? Find out in our full research report (it’s free for active Edge members).
Philip Morris (PM) Q4 CY2025 Highlights:
- Revenue: $10.36 billion vs analyst estimates of $10.31 billion (6.8% year-on-year growth, in line)
- Adjusted EPS: $1.70 vs analyst estimates of $1.70 (in line)
- Adjusted EBITDA: $3.70 billion (35.7% margin, 4.9% year-on-year decline)
- Operating Margin: 32.6%, down from 33.6% in the same quarter last year
- Market Capitalization: $284.6 billion
StockStory’s Take
Philip Morris’s fourth quarter results were driven by strong growth in its smoke-free portfolio, with management emphasizing double-digit volume gains for its IQOS, ZYN, and VIVE products across multiple regions. CEO Jacek Olczak called attention to the accelerated adoption of smoke-free alternatives, stating, “Our leading global position in smoke-free products enables us to deliver a fifth consecutive year of positive volumes.” Growth was broad-based, including notable gains in Europe, rapid expansion in new markets like Taiwan, and resilience in combustibles despite normalized industry declines and specific supply chain disruptions, particularly in Turkey.
Looking forward, the company’s guidance is shaped by ongoing investment in smoke-free innovation, regulatory developments—especially in the U.S. and Japan—and continued momentum for premium products. Management highlighted plans to launch new offerings, such as ZYN Ultra pending FDA approval, and anticipated excise tax increases in Japan, which are expected to pressure category growth temporarily. Olczak noted, “We target substantial further growth from IQOS in Japan in the years to come,” while also anticipating a significant acceleration in U.S. product launches, contingent on regulatory clearance.
Key Insights from Management’s Remarks
Management attributed the latest quarter’s performance to the expanding smoke-free portfolio, efficient pricing strategies, and continued investment in emerging markets, while cautioning about upcoming regulatory and tax headwinds.
- Smoke-free product growth: Double-digit volume gains in IQOS, ZYN, and VIVE drove overall business performance, with smoke-free net revenues now accounting for over 41% of total sales. IQOS shipments and adjusted sales both grew around 11%, while ZYN shipments in the U.S. expanded by 37% despite earlier supply constraints.
- Geographic expansion: The smoke-free portfolio reached 106 markets, with 52 deploying the multi-category strategy. Notable new launches included ZYN in Argentina and IQOS in Taiwan, contributing to broad-based international growth. Management cited strong uptake in Italy, Taiwan, and multiple European cities, with over 27 markets now exceeding the 50% smoke-free revenue milestone.
- Pricing and margin management: Strategic pricing, particularly in combustibles, offset volume declines and unfavorable mix, supporting a 4.1% positive pricing impact. However, an operating margin decline to 32.6% reflected higher investment in marketing and brand development for smoke-free products.
- Combustible segment resilience: Despite an industry-wide decline in traditional cigarette volumes, Philip Morris maintained robust pricing power and portfolio resilience, with Marlboro hitting a record market share outside China. Supply chain issues in Turkey were noted but did not materially affect global performance.
- Innovation and brand investments: Continued emphasis on brand-building and innovation was highlighted, including the upcoming ZYN and IQOS product launches and a partnership with Ferrari for global brand exposure. Management underscored that further digitalization and organizational changes are expected to support future growth.
Drivers of Future Performance
Philip Morris’s outlook centers on ongoing smoke-free product development, regulatory actions in key markets, and disciplined cost management to support margin expansion.
- Regulatory and tax headwinds: Anticipated excise tax increases in Japan and potential U.S. regulatory changes, such as state-level nicotine pouch taxation, may temporarily slow category growth, particularly for IQOS and ZYN. Management expects shipment volatility and pricing adjustments to impact short-term results, but remains confident in long-term category resilience.
- Innovation pipeline and U.S. expansion: The company is preparing for new product launches, notably ZYN Ultra pending FDA approval, and the eventual introduction of IQOS ILUMA in the U.S. These initiatives are expected to drive high-single-digit smoke-free volume growth and expand the addressable market, although timing remains subject to regulatory review.
- Operational efficiencies and cost savings: Ongoing investments in digitalization and artificial intelligence are projected to enhance back-office and supply chain efficiency. Management reiterated its aim for $2 billion in cost savings over the 2024-2026 period, with further gains expected to support operating margin improvement.
Catalysts in Upcoming Quarters
In the coming quarters, our analyst team will closely monitor (1) the pace of regulatory developments and product approvals for ZYN Ultra and IQOS ILUMA in the U.S., (2) the effect of Japanese excise tax increases on IQOS category growth and pricing elasticity, and (3) continued adoption rates of smoke-free products in emerging and established markets. Execution in digitalization and cost efficiency will also be crucial to sustaining margin progress.
Philip Morris currently trades at $182.44, in line with $182 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.